NCT07640100Not yet recruiting
EFFECTS OF AEROBIC AND RESISTANCE TRAINING ON IMMUNE FUNCTION IN MULTIPLE SCLEROSIS
EVALUATION OF THE EFFECTS OF AEROBIC AND RESISTANCE EXERCISES ON THE IMMUNE SYSTEM AND FUNCTIONAL CAPACITY IN MULTIPLE SCLEROSIS
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
Background: Multiple Sclerosis (MS) is a chronic immune-mediated, inflammatory, and neurodegenerative central nervous system disorder characterized by axonal damage. This damage leads to various debilitating symptoms such as muscle weakness, fatigue, balance loss, and cognitive decline. While reductions in aerobic capacity and muscle strength are secondary manifestations of MS, physical exercise serves as a crucial therapeutic strategy to manage symptoms and optimize functionality. Rationale: Aerobic exercise exerts anti-inflammatory effects by reducing adipose tissue mass, promoting anti-inflammatory macrophage polarization, and downregulating toll-like receptors. It also modulates the altered T-helper cytokine balance in MS (characterized by elevated proinflammatory cytokines like IL-1, IL-6, IL-17, IFN-γ, TNF-α and decreased anti-inflammatory IL-10), potentially slowing myelin destruction. Concurrently, progressive resistance training (typically at 60%-80% of maximum voluntary contraction) has been shown to improve muscle strength and reduce perceived fatigue in this population. However, data regarding the specific impacts of these exercise modalities on the immune system remain limited. Objective:The aim of this randomized controlled trial is to investigate and compare the effects of AEROBIC AND STRENGTHENING (RESISTANCE) EXERCISES ON THE IMMUNE SYSTEM PARAMETERS (SPECIFICALLY CYTOKINE PROFILES) AND OVERALL FUNCTIONALITY IN INDIVIDUALS DIAGNOSED WITH MULTIPLE SCLEROSIS.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 2 Jun 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 30 Aug 2026
- Lead sponsor
- Seda Saka
- Diseases
- Multiple sclerosis
- NCT number
- NCT07640100
What you commit to
- Study type: Interventional
- Planned participants: 45
- From 1 Jun 2026 to the primary completion date, 30 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Having a high baseline level of physical activity.
- Experiencing an acute MS relapse or having a history of a relapse within the past 3 months.
- Presence of any orthopedic or bone pathology that would prevent participation in the exercise program.
- Concomitant diagnosis of any known neuromuscular or immunological disease other than MS.
- Initiating immunomodulatory therapy within the last 6 months.
- Presence of visual involvement or symptomatic diplopia.
- High-grade lower extremity spasticity, defined as a Modified Ashworth Scale (MAS) score of 3 or 4.
- Abnormal white blood cell (WBC) count outside the normal reference range of 4,000-10,000 cells/µL.
- Presence of any severe cardiopulmonary condition that would contraindicate or prevent participation in physical exercise.
Who the study is looking for
- Diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS). Aged between 19 and 45 years. Expanded Disability Status Scale (EDSS) score between 0.5 and 3.5. Not currently receiving steroid therapy (or having no recent corticosteroid treatment within the specified washout period).
Age in the registry: 19 years to 45 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Van Regional Training and Research Hospital Coordinator of this site? Confirm its status | Van | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.